Edition:
United States

Myriad Genetics Inc (MYGN.O)

MYGN.O on Nasdaq

16.99USD
8 Dec 2016
Change (% chg)

-- (--)
Prev Close
$16.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,843,186
52-wk High
$44.57
52-wk Low
$15.92

MYGN.O

Chart for MYGN.O

About

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is... (more)

Overall

Beta: 0.36
Market Cap(Mil.): $1,162.39
Shares Outstanding(Mil.): 68.42
Dividend: --
Yield (%): --

Financials

  MYGN.O Industry Sector
P/E (TTM): 12.88 55.22 30.65
EPS (TTM): 1.32 -- --
ROI: 11.30 7.07 15.23
ROE: 13.69 10.66 16.56

BRIEF-Camber Capital Management reports 5.53 pct passive stake in Myriad Genetics

* Camber Capital Management LLC reports 5.53 percent passive stake in Myriad Genetics Inc as of November 16 - sec filing Source text : http://bit.ly/2fuddBZ Further company coverage:

Nov 28 2016

BRIEF-Myriad will seek Japanese regulatory approval for Bracanalysis CDX

* Myriad will seek Japanese regulatory approval for Bracanalysis Cdx

Nov 07 2016

BRIEF-Myriad Genetics reports fiscal first-quarter 2017 financial results

* Sees fiscal second-quarter 2017 revenue $188-$190 million; sees Q2 2017 adjusted eps $0.23-$0.25; sees Q2 2017 GAAP EPS $0.06-$0.08

Nov 01 2016

BRIEF-Myriad Genetics's melanoma test effectively diagnosed patients in study

* The myriad mypath melanoma test effectively diagnosed patients in the largest outcomes-based study for a melanoma diagnostic Source text for Eikon: Further company coverage:

Oct 27 2016

BRIEF-Myriad's BRACanalysis CDx test accurately identified patients who may benefit from treatment with Olaparib

* Says its BRACanalysis CDx test accurately identified patients who may benefit from treatment with Olaparib

Oct 26 2016

BRIEF-Myriad RBM announces agreement with Sanofi

* Announces an agreement with Sanofi to measure predictive cardiovascular biomarkers in patients with diabetes

Oct 25 2016

BRIEF-Myriad Genetics, ION Solutions to partner for cancer testing

* Company, ION Solutions entered into a relationship to deliver hereditary cancer test results and services to ION member practices Source text for Eikon: Further company coverage:

Oct 21 2016

BRIEF-Myriad Genetics to enter into a credit agreement

* Pursuant to credit agreement, Myriad borrowed term loans in an aggregate principal amount of $200.0 million

Sep 01 2016

BRIEF-Myriad Genetics reports Q4 earnings per share $0.32

* Q4 earnings per share view $0.37 -- Thomson Reuters I/B/E/S

Aug 09 2016

BRIEF-Myriad Genetics signs definitive agreement to buy Assurex Health

* Myriad Genetics signs definitive agreement to acquire Assurex Health

Aug 03 2016

Earnings vs. Estimates